Published in Vaccine Weekly, December 11th, 2002
Genzyme Molecular Oncology, a division of Genzyme Corporation, is the first commercial entity in the United States to pursue development of patient-specific cancer vaccines produced using this electrical fusion approach.
The phase I/II kidney cancer trial is now enrolling patients in Boston at the Beth Israel Deaconess Medical Center. Enrollment also is expected to begin shortly at the Dana-Farber Cancer Institute. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly